Y-Intercept (HK)’s Arbutus Biopharma ABUS Stock Holding History

Y-Intercept (HK)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-66,056	Closed	-$300K	–	1485
2025 Q3	$300K	Buy	+66,056	New	+$243K	0.01%	1377

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Y-Intercept (HK)'s ABUS Position: Q4 2025 in Review

Y-Intercept (HK) sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 66,056 shares — an estimated $300K sold.

Y-Intercept (HK) first reported a position in ABUS in Q3 2025 and held it in 1 quarter. The position peaked at $300K in Q3 2025. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

Y-Intercept (HK) reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
Y-Intercept (HK) sold 66,056 Arbutus Biopharma shares in Q4 2025, an estimated $300K.
Y-Intercept (HK) first reported a position in Arbutus Biopharma in Q3 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Arbutus Biopharma position peaked at $300K in Q3 2025.
172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.